Gene Editing Market Competitor Analysis: Opportunities and Challenges

The global gene editing market size in terms of revenue, was estimated at .3 billion in 2023 and is projected to reach .6 billion by 2028, showcasing a remarkable compound annual growth rate (CAGR) of 15.0% from 2023 to 2028.

Download PDF Brochure:

OPPORTUNITY: Expanding pipeline for gene therapy

The expanding pipeline for gene therapy in the gene editing industry presents significant opportunities for advancements in treating genetic disorders and other diseases. Gene therapy involves the delivery of therapeutic genes or gene editing tools into the patient’s cells to correct genetic mutations, restore normal gene function, or introduce therapeutic genes for targeted treatment. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and the treatment of previously incurable diseases.

CHALLENGE: High equipment costs

The costs associated with gene editing equipment can be substantial. For instance, gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, electroporation devices, and fluorescence microscopes. These instruments can have high price tags, ranging from thousands to millions of dollars. In addition to equipment costs, procuring quality reagents, such as nucleases, guide RNAs, and donor templates, can contribute to the overall expenses.

Key Players in the Gene Editing Market

Let’s delve into the strategies and contributions of three major players shaping the gene editing market growth:

  1. Thermo Fisher Scientific (US): Thermo Fisher Scientific is a powerhouse in the gene editing arena, offering a comprehensive and integrated portfolio of solutions and services. With a strong emphasis on clinical science, laboratory research, and analysis, the company has carved a niche for itself in gene modification and precision genome editing. Thermo Fisher Scientific’s high-efficiency delivery systems facilitate the development of gene expression systems, modified genes, and stable engineered cell lines. The company’s genome editing technologies, including CRISPR-Cas9 and TAL effectors, are accessible through licensing, supporting various applications such as contract manufacturing services, research, vaccine development, animal health, biofuels, and diagnostics.
  2. Merck KGaA (Germany): Merck KGaA, one of the top contenders in the genome editing market, collaborates closely with pharmaceutical and biotechnology companies engaged in genomic and personalized medicine. The company’s strength lies in licensing its proprietary editing technology to bolster its market presence. In a significant move, Merck signed a collaboration and license agreement in March 2022 with BetterSeeds, an Israeli company focused on developing new plant breeds using CRISPR technology. This strategic agreement, facilitated through Merck’s Life Science division, MilliporeSigma, aims to expand the reach of its proprietary CRISPR Cas9 technology, further solidifying its position in the gene editing domain.
  3. GenScript (China): GenScript, a prominent player in the gene editing market, boasts a comprehensive portfolio of products and services dedicated to gene editing. The company’s strong foothold in CRISPR technology is the result of substantial investments in research and development. GenScript offers validated CRISPR products, services, and resources through its partnership with the Broad Institute of MIT and Harvard, led by renowned scientist Feng Zhang. GenScript’s expertise in CRISPR extends across cell therapy, CAR-T cell therapy, and gene therapy applications, making it a formidable competitor in the market.

Get More Insights – Download Free PDF Sample:

The global gene editing industry is segmented across five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these, North America stands out as the largest regional market for gene editing, with the United States leading as the key revenue contributor. The US has become a focal point for substantial investments and funding from venture capitalists, government agencies, and private entities within the gene editing space. This influx of capital has catalyzed extensive research and development efforts and facilitated the translation of gene editing technologies into viable commercial applications. Consequently, the availability of financial resources has played a pivotal role in nurturing the growth of gene editing companies and propelling advancements in therapeutic interventions within the region.

Related News & Article:–marketsandmarkets-301877363.html

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441